ATE406383T1 - Verkürzte tau proteine - Google Patents

Verkürzte tau proteine

Info

Publication number
ATE406383T1
ATE406383T1 AT03763763T AT03763763T ATE406383T1 AT E406383 T1 ATE406383 T1 AT E406383T1 AT 03763763 T AT03763763 T AT 03763763T AT 03763763 T AT03763763 T AT 03763763T AT E406383 T1 ATE406383 T1 AT E406383T1
Authority
AT
Austria
Prior art keywords
molecules
amino acids
terminal amino
tau
detectable
Prior art date
Application number
AT03763763T
Other languages
English (en)
Inventor
Eva Kontsekova
Original Assignee
Axon Neuroscience
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axon Neuroscience filed Critical Axon Neuroscience
Application granted granted Critical
Publication of ATE406383T1 publication Critical patent/ATE406383T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0312—Animal model for Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Neurology (AREA)
  • Veterinary Medicine (AREA)
  • Environmental Sciences (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Psychiatry (AREA)
AT03763763T 2002-07-12 2003-07-09 Verkürzte tau proteine ATE406383T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT10532002 2002-07-12
PCT/EP2003/007389 WO2004007547A2 (en) 2002-07-12 2003-07-09 Truncated tau proteins

Publications (1)

Publication Number Publication Date
ATE406383T1 true ATE406383T1 (de) 2008-09-15

Family

ID=30120907

Family Applications (2)

Application Number Title Priority Date Filing Date
AT03763764T ATE391781T1 (de) 2002-07-12 2003-07-09 Transgenes tier welches das trunkierte alzheimer tau protein exprimiert
AT03763763T ATE406383T1 (de) 2002-07-12 2003-07-09 Verkürzte tau proteine

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT03763764T ATE391781T1 (de) 2002-07-12 2003-07-09 Transgenes tier welches das trunkierte alzheimer tau protein exprimiert

Country Status (10)

Country Link
US (5) US20060167227A1 (de)
EP (3) EP1521831B1 (de)
JP (3) JP4414332B2 (de)
CN (2) CN100572392C (de)
AT (2) ATE391781T1 (de)
AU (2) AU2003246664B2 (de)
DE (2) DE60320258T2 (de)
DK (2) DK1521831T3 (de)
ES (2) ES2311734T3 (de)
WO (2) WO2004007722A2 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4414332B2 (ja) * 2002-07-12 2010-02-10 アクソン・ニューロサイエンス・フォルシュングス−ウント・エントヴィックルングス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング アルツハイマーｔａｕタンパク質を発現するトランスジェニック動物
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US7609947B2 (en) 2004-09-10 2009-10-27 Panasonic Corporation Method and apparatus for coordinating playback from multiple video sources
BRPI0619249A2 (pt) 2005-11-30 2011-09-20 Abbott Lab anticorpos anti-globulÈmeros-aß, frações que se ligam a antìgeno destes, hibridomas correspondentes, ácidos nucléicos, vetores, células hospedeiras, métodos de produzir os ditos anticorpos, composições compreendendo os ditos anticorpos, usos dos ditos anticorpos e métodos de usar os ditos anticorpos
PT1976877E (pt) 2005-11-30 2014-04-29 Abbvie Inc Anticorpos monoclonais contra proteína beta-amilóide e suas utilizações
KR100734815B1 (ko) 2006-02-15 2007-07-09 대한민국 Ｈｔａｕ24 유전자를 발현하는 형질전환 치매 마우스 및 그제조방법
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP2124952A2 (de) 2007-02-27 2009-12-02 Abbott GmbH & Co. KG Verfahren zur behandlung von amyloidosen
EP2558494B1 (de) 2010-04-15 2018-05-23 AbbVie Inc. Amyloid-beta-bindende proteine
CN105348387B (zh) 2010-08-14 2020-08-25 Abbvie 公司 β淀粉样蛋白结合蛋白
CN102058619A (zh) * 2010-12-08 2011-05-18 山西医科大学 一种阿尔茨海默病复合动物模型的制备方法
JP2014502510A (ja) * 2010-12-31 2014-02-03 ゼウス サイエンティフィック、インク． 分子核酸ベースの技術を使用している細胞生存度を決定する改良された方法
US8703137B2 (en) 2011-01-31 2014-04-22 Intellect Neurosciences Inc. Treatment of tauopathies
EP2709728B1 (de) 2011-05-20 2019-01-23 Oligomerix, Inc. Tau-protease-anwendungsverfahren
US9518101B2 (en) * 2011-09-19 2016-12-13 Axon Neuroscience Se Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease
JP6345655B2 (ja) 2012-07-03 2018-06-20 ワシントン・ユニバーシティＷａｓｈｉｎｇｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ タウに対する抗体
DK2885010T3 (da) 2012-08-16 2020-02-03 Ipierian Inc Fremgangsmåder til behandling med tauopati
US9200068B2 (en) 2012-12-18 2015-12-01 Regents Of The University Of Minnesota Compositions and methods related to tauopathy
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
JP2017512751A (ja) 2014-02-14 2017-05-25 アイピエリアン，インコーポレイティド タウペプチド、抗タウ抗体、およびそれらの使用方法
WO2015165961A1 (en) 2014-04-29 2015-11-05 Affiris Ag Treatment and prevention of alzheimer's disease (ad)
TW202136296A (zh) 2014-06-27 2021-10-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗-tau抗體
HRP20210124T1 (hr) 2014-11-19 2021-03-19 Axon Neuroscience Se Humanizirana tau antitijela u alzheimerovoj bolesti
SG11201706293XA (en) * 2015-02-04 2017-09-28 Hoffmann La Roche Tau antisense oligomers and uses thereof
WO2017172764A1 (en) * 2016-04-01 2017-10-05 The Regents Of The University Of California Modified cell line and method of determining tauopathies
KR101997319B1 (ko) 2016-06-21 2019-07-08 전남대학교산학협력단 이형태체 항원인식 항체 생산을 유도하는 플라젤린 백신보조제 기반의 백신의 제조 및 그 응용
CA3047132A1 (en) * 2016-12-30 2018-07-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for the detection of tau protein aggregates
WO2018175581A1 (en) * 2017-03-21 2018-09-27 The Jackson Laboratory A GENETICALLY MODIFIED MOUSE EXPRESSING HUMAN APOE4 MOUSE Trem2.p.R47H AND METHODS OF USE THEREOF
EP3658172A4 (de) 2017-07-25 2021-05-05 TrueBinding, Inc. Behandlung von krebs durch blockierung der interaktion von tim-3 und seinem liganden
WO2019186276A2 (en) 2018-03-28 2019-10-03 Axon Neuroscience Se Antibody-based methods of detecting and treating alzheimer's disease
CN113711036B (zh) 2019-01-30 2025-03-18 真和制药有限公司 抗gal3抗体及其用途
CA3135170A1 (en) 2019-04-05 2020-10-08 Tauc3 Biologics Limited Anti-tauc3 antibodies and uses thereof
JP7181438B2 (ja) 2019-08-06 2022-11-30 アプリノイア セラピューティクス リミテッド 病理学的タウ種に結合する抗体及びその使用
CN110679549B (zh) * 2019-11-05 2021-08-20 南通大学 一种阿尔茨海默病小鼠模型的构建方法
CN116157151A (zh) 2020-05-26 2023-05-23 真和制药有限公司 通过阻断半乳凝素-3治疗炎性疾病的方法
MX2024003519A (es) 2021-09-24 2024-04-01 Alnylam Pharmaceuticals Inc Composiciones de agentes de acido ribonucleico de interferencia (arni) de proteina tau asociada a microtubulos (mapt) y sus metodos de uso.
CN116554342A (zh) * 2022-01-29 2023-08-08 元本(珠海横琴)生物科技有限公司 一种融合表达Tau-4R蛋白的大肠杆菌工程菌株

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06239899A (ja) 1993-02-12 1994-08-30 Teijin Ltd ヒトタウ蛋白に対する抗体、並びに該抗体を利用する体液中のヒトタウ蛋白の測定方法
GB9506197D0 (en) * 1995-03-27 1995-05-17 Hoffmann La Roche Inhibition of tau-tau association.
WO1999062548A1 (en) 1998-06-01 1999-12-09 Advanced Research And Technology Institute Methods and compositions for diagnosing tauopathies
EP1216297A2 (de) * 1999-07-02 2002-06-26 Janssen Pharmaceutica N.V. Doppeltransgene tiermodelle für neurodegenerative krankheite
EP1214598B1 (de) * 1999-09-09 2006-05-17 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Screening nach inhibitoren von "gepaarten helikalen filamenten"
WO2001053340A2 (en) * 2000-01-21 2001-07-26 Pharmacia & Upjohn Company Transgenic mouse model of human neurodegenerative disease
WO2001065252A1 (en) * 2000-02-29 2001-09-07 The Nathan S. Kline Institute For Psychiatric Research Transgenic mice comprising a genomic human tau transgene
GB0100119D0 (en) * 2001-01-03 2001-02-14 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
GB0101049D0 (en) * 2001-01-15 2001-02-28 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
AT500379B8 (de) * 2001-02-02 2009-08-15 Axon Neuroscience Tau-proteine
US20020164657A1 (en) * 2001-02-23 2002-11-07 Sharma Satish K. Assays for assessing A beta-Tau aggregation
JP4414332B2 (ja) * 2002-07-12 2010-02-10 アクソン・ニューロサイエンス・フォルシュングス−ウント・エントヴィックルングス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング アルツハイマーｔａｕタンパク質を発現するトランスジェニック動物

Also Published As

Publication number Publication date
JP4414332B2 (ja) 2010-02-10
AU2003253044B2 (en) 2009-08-13
CN100577803C (zh) 2010-01-06
ATE391781T1 (de) 2008-04-15
US20160106077A1 (en) 2016-04-21
WO2004007547A2 (en) 2004-01-22
WO2004007722A3 (en) 2004-03-25
EP1521831A2 (de) 2005-04-13
WO2004007722A2 (en) 2004-01-22
EP1521831B1 (de) 2008-04-09
US9161520B2 (en) 2015-10-20
DK1521831T3 (da) 2008-06-30
EP1995255A1 (de) 2008-11-26
AU2003246664B2 (en) 2007-06-14
US9485972B2 (en) 2016-11-08
US20130179997A1 (en) 2013-07-11
US8288608B2 (en) 2012-10-16
CN100572392C (zh) 2009-12-23
CN1668745A (zh) 2005-09-14
JP2005532802A (ja) 2005-11-04
JP2006515270A (ja) 2006-05-25
US20060112437A1 (en) 2006-05-25
DE60320258T2 (de) 2009-06-25
DE60323231D1 (de) 2008-10-09
US20100063250A1 (en) 2010-03-11
WO2004007547A3 (en) 2004-07-22
AU2003253044A1 (en) 2004-02-02
DK1521774T3 (da) 2008-10-27
AU2003246664A1 (en) 2004-02-02
ES2311734T3 (es) 2009-02-16
EP1521774A2 (de) 2005-04-13
EP1521774B1 (de) 2008-08-27
DE60320258D1 (de) 2008-05-21
CN1668641A (zh) 2005-09-14
JP2009143906A (ja) 2009-07-02
US20060167227A1 (en) 2006-07-27
ES2304146T3 (es) 2008-09-16
JP4308760B2 (ja) 2009-08-05

Similar Documents

Publication Publication Date Title
DE60323231D1 (de) Verkürzte tau proteine
ATE461941T1 (de) Antikörper gegen alzheimer spezifische tau proteine mit abnormaler konformation
ATE169304T1 (de) Biologisch aktive peptide aus funktionellen domaenen des bakteriziden/ die permeabilitaet erhoehenden proteins und ihre verwendung
CY1106899T1 (el) Διαμορφωτες συσσωματωσης βητα-αμυλοειδων πεπτιδιων που περιλαμβανουν d-αμινοξεα
DE60128916D1 (de) Neues, physiologisch aktives peptid und dessen verwendung
ATE516304T1 (de) Nrg-2 nukleinsäuren, polypeptide und diagnostische / therapeutische methoden
EP1541686A4 (de) Antikörperkonstruktion unter verwendung einer mrl/lpr-maus
CA2268029A1 (en) Therapeutic and diagnostic applications of laminin and laminin-derived protein fragments
BRPI0616712B8 (pt) método para amidar polipeptídeos com terminais c de aminoácido básicos por meio de endoproteases específicas
DE50212280D1 (de) Verwendung von hmgb-proteinen und dafür codierenden nukleinsäuren
ATE344325T1 (de) Neisseria lactoferrin-bindendes protein
EP1023906A4 (de) Verstärker für antikörper gegen lymphoiden tumor
ATE441713T1 (de) Tumorantigenprotein und dessen verwendung
DE60126602D1 (de) Neue collectine
BRPI0308978A8 (pt) fragmentos de peptídeos sintéticos ativos
ATE346091T1 (de) Neues diagnostisches reagens und kit zur erkennung von rickettsiose
DE69712182D1 (de) Peptide und ihre verwendung in der therapie von krankheiten des zöliakie-formenkreises
DE60321443D1 (de) Screening-verfahren für eine prophylaktische und therapeutische Substanz für eine Nierenerkrankung
ATE328082T1 (de) Verkürztes bard1 protein und dessen diagnostische und therapeutische anwendungen
DE602006017806D1 (de) Behandlung von neurodegeneration
SG170757A1 (en) Polypeptide having esterase activity and recombinant esterase and use thereof
WO2001000655A3 (en) Therapeutic peptides derived from subsequences of bpi
WO2004058811A3 (en) Crystal structures of yhhf polypeptides
WO2003095644A1 (fr) Nouvelles proteines et adn pour lesdites proteines
BR0107799A (pt) Proteìna de interação de wt1 wtip

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1521774

Country of ref document: EP